{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T11:32:04Z","timestamp":1785929524925,"version":"3.56.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"DOI":"10.1186\/s12936-025-05337-2","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T16:36:00Z","timestamp":1742315760000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Increasing day three parasitaemia is observed after treatment of patients with artemether-lumefantrine and single dose of primaquine for uncomplicated Plasmodium falciparum malaria in Arbaminch Zuria district, Southwest Ethiopia"],"prefix":"10.1186","volume":"24","author":[{"given":"Bontu","family":"Abate","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bokretsion Gidey","family":"Brhane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsegahun","family":"Manyazewal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussien","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonas","family":"Wuletaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moges","family":"Kassa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mesay","family":"Hailu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Getachew","family":"Tollera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geremew","family":"Tasew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashenafi","family":"Assefa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eyasu","family":"Makonnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,18]]},"reference":[{"key":"5337_CR1","unstructured":"WHO. Guidelines for malaria 2023 [Internet]. Geneva, World Health Organization, 2023. Available from: https:\/\/www.who.int\/publications\/i\/item\/guidelines-for-malaria."},{"key":"5337_CR2","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.pt.2016.11.006","volume":"33","author":"IN Nkumama","year":"2017","unstructured":"Nkumama IN, O\u2019Meara WP, Osier FHA. Changes in malaria epidemiology in Africa and new challenges for elimination. Trends Parasitol. 2017;33:128\u201340.","journal-title":"Trends Parasitol"},{"key":"5337_CR3","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s44197-024-00228-2","volume":"14","author":"J Li","year":"2024","unstructured":"Li J, Docile HJ, Fisher D, Pronyuk K, Zhao L. Current status of malaria control and elimination in Africa: epidemiology, diagnosis, treatment, progress and challenges. J Epidemiol Glob Health. 2024;14:561\u201379.","journal-title":"J Epidemiol Glob Health"},{"key":"5337_CR4","unstructured":"WHO. World malaria report 2024. Geneva, World Health Organization, 2024. https:\/\/www.who.int\/teams\/global-malaria-programme\/reports\/world-malaria-report-2024"},{"key":"5337_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e15252","volume":"9","author":"TZ Nigussie","year":"2023","unstructured":"Nigussie TZ, Zewotir TT, Muluneh EK. Seasonal and spatial variations of malaria transmissions in northwest Ethiopia: Evaluating climate and environmental effects using generalized additive model. Heliyon. 2023;9: e15252.","journal-title":"Heliyon"},{"key":"5337_CR6","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12936-024-04854-w","volume":"23","author":"A Mandefro","year":"2024","unstructured":"Mandefro A, Tadele G, Mekonen B, Golassa L. Analysing the six-year malaria trends at Metehara Health Centre in Central Ethiopia: the impact of resurgence on the 2030 elimination goals. Malar J. 2024;23:32.","journal-title":"Malar J"},{"key":"5337_CR7","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s40249-017-0372-5","volume":"6","author":"MB Ayalew","year":"2017","unstructured":"Ayalew MB. Therapeutic efficacy of artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Ethiopia: a systematic review and meta-analysis. Infect Dis Poverty. 2017;6:157.","journal-title":"Infect Dis Poverty"},{"key":"5337_CR8","unstructured":"FMOH. Diagnosis and treatment guidelines for health workers in Ethiopia. 2nd Edn. Ethiopia, Addis Ababa. 2004. Available on-line: https:\/\/www.medbox.org\/preview\/5333fe20-1850-4d30-9fbe-731f1fcc7b89\/doc.pdf (accessed on 24 April 2024)"},{"key":"5337_CR9","unstructured":"WHO. Methods for surveillance of antimalarial drug efficacy. Geneva, World Health Organization [Internet]. 2009. Available from: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/44048\/9789241597531_eng.pdf?sequence=1%0Ahttp:\/\/www.who.int\/malaria\/publications\/atoz\/9789241597531\/en\/"},{"key":"5337_CR10","unstructured":"Federal Democratic Republic of Ethiopia Ministry of Health. National Malaria Guidelines. 4th Edn. 2017. https:\/\/reliefweb.int\/report\/ethiopia\/ethiopia-national-malaria-guidelines-fourth-edition-november-2017"},{"key":"5337_CR11","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12936-024-04848-8","volume":"23","author":"A Assefa","year":"2024","unstructured":"Assefa A, Fola AA, Tasew G. Emergence of Plasmodium falciparum strains with artemisinin partial resistance in East Africa and the Horn of Africa: is there a need to panic? Malar J. 2024;23:34.","journal-title":"Malar J"},{"key":"5337_CR12","doi-asserted-by":"crossref","unstructured":"Nega D, Assefa A, Mohamed H, Solomon H. Therapeutic efficacy of artemether-lumefantrine (Coartem) in Ttreating uncomplicated P . falciparum malaria in Metehara, Eastern Ethiopia: regulatory clinical study. PLoS One. 2016;11:e0154618.","DOI":"10.1371\/journal.pone.0154618"},{"key":"5337_CR13","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.2147\/TCRM.S113603","volume":"12","author":"F Wudneh","year":"2016","unstructured":"Wudneh F, Assefa A, Nega D, Mohammed H, Solomon H, Kebede T, et al. Open-label trial on efficacy of artemether\/lumefantrine against the uncomplicated Plasmodium falciparum malaria in Metema district. Northwestern Ethiopia Ther Clin Risk Manag. 2016;12:1293\u2013300.","journal-title":"Northwestern Ethiopia Ther Clin Risk Manag"},{"key":"5337_CR14","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/s12936-020-03307-4","volume":"19","author":"A Abamecha","year":"2020","unstructured":"Abamecha A, Yilma D, Addisu W, El AH, Ibenthal A, Noedl H, et al. Therapeutic efficacy of artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Chewaka District. Ethiopia Malar J. 2020;19:240.","journal-title":"Ethiopia Malar J"},{"key":"5337_CR15","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s12936-015-0775-3","volume":"14","author":"G Getnet","year":"2015","unstructured":"Getnet G, Fola AA, Alemu A, Getie S, Fuehrer HP, Noedl H. Therapeutic efficacy of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Enfranze, north-west Ethiopia. Malar J. 2015;14:258.","journal-title":"Malar J"},{"key":"5337_CR16","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2147\/TCRM.S127571","volume":"13","author":"T Deressa","year":"2017","unstructured":"Deressa T, Seid ME, Birhan W, Aleka Y, Tebeje BM. In vivo efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria in Dembia District, northwest Ethiopia. Ther Clin Risk Manag. 2017;13:201\u20136.","journal-title":"Ther Clin Risk Manag"},{"key":"5337_CR17","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1186\/s12936-015-0826-9","volume":"14","author":"SK Mekonnen","year":"2015","unstructured":"Mekonnen SK, Medhin G, Berhe N, Clouse RM, Aseffa A. Efficacy of artemether-lumefantrine therapy for the treatment of uncomplicated Plasmodium falciparum malaria in Southwestern Ethiopia. Malar J. 2015;14:317.","journal-title":"Malar J"},{"key":"5337_CR18","unstructured":"WHO. Policy brief on single dose primaquine as a gametocytocide in Plasmodium falciparum malaria. Geneva, World Health Organization, 2015. Available online: https:\/\/www.who.int\/publications\/i\/item\/WHO-HTM-GMP-2015.1) (accessed on \u2013 30Apr 2024)."},{"key":"5337_CR19","first-page":"266","volume":"23","author":"D Woldesenbet","year":"2024","unstructured":"Woldesenbet D, Birhanie M, Abere A, Zeleke AJ, Bezabih MK, Semaw M, et al. Therapeutic efficacy and safety of artemether-lumefantrine combination therapy for the treatment of uncomplicated Plasmodium falciparum malaria at Teda Health Centre. Northwest Ethiopia Malar J. 2024;23:266.","journal-title":"Northwest Ethiopia Malar J"},{"key":"5337_CR20","doi-asserted-by":"publisher","first-page":"363","DOI":"10.2147\/IDR.S223873","volume":"13","author":"A Abossie","year":"2020","unstructured":"Abossie A, Yohanes T, Nedu A, Tafesse W, Damitie M. Prevalence of malaria and associated risk factors among febrile children under five years: a cross-sectional study in Arba Minch Zuria district, south Ethiopia. Infect Drug Resist. 2020;13:363\u201372.","journal-title":"Infect Drug Resist"},{"key":"5337_CR21","unstructured":"WHO. Methods and techniques for clinical trials on antimalarial drug efficacy\u202f: genotyping to identify parasite populations\u202f: informal consultation organized by the Medicines for Malaria Venture and cosponsored by the World Health Organization, 29\u201331 May 2007, Amsterdam, The Netherlands. World Health Organization; 2008. 44 p."},{"key":"5337_CR22","doi-asserted-by":"publisher","first-page":"e82","DOI":"10.1086\/657120","volume":"51","author":"H Noedl","year":"2010","unstructured":"Noedl H, Se Y, Sriwichai S, Schaecher K, Teja-Isavadharm P, Smith B, et al. Artemisinin resistance in Cambodia: a clinical trial designed to address an emerging problem in Southeast Asia. Clin Infect Dis. 2010;51:e82\u20139.","journal-title":"Clin Infect Dis"},{"key":"5337_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0176004","volume":"12","author":"M Teklemariam","year":"2017","unstructured":"Teklemariam M, Assefa A, Kassa M, Mohammed H, Mamo H. Therapeutic efficacy of artemether- lumefantrine against uncomplicated Plasmodium falciparum malaria in a high- transmission area in northwest Ethiopia. PLoS ONE. 2017;12: e0176004.","journal-title":"PLoS ONE"},{"key":"5337_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1756-3305-3-1","volume":"3","author":"A Assefa","year":"2010","unstructured":"Assefa A, Moges K, Gemechu T, Husen M, Abebe A, Tesfaye M. Therapeutic efficacy of artemether-lumefantrine ( Coartem \u00ae) against Plasmodium falciparum in Kersa southwest Ethiopia. Parasit Vectors. 2010;3:1.","journal-title":"Parasit Vectors"},{"key":"5337_CR25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12936-022-04436-8","volume":"22","author":"K Gubae","year":"2023","unstructured":"Gubae K, Mohammed H, Sime H, Hailgiorgis H, Mare AK, Gidey B, et al. Safety and therapeutic efficacy of artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria at Shecha health centre, Arba Minch. Ethiopia Malar J. 2023;22:9.","journal-title":"Ethiopia Malar J"},{"key":"5337_CR26","first-page":"7371681","volume":"2020","author":"A Derbie","year":"2020","unstructured":"Derbie A, Mekonnen D, Adugna M, Yeshitela B, Woldeamanuel Y, Abebe T. Therapeutic efficacy of artemether-lumefantrine ( Coartem \u00ae) for the treatment of uncomplicated falciparum malaria in Africa\u202f: a systematic review. Parasitol Res. 2020;2020:7371681.","journal-title":"Parasitol Res"},{"key":"5337_CR27","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/1475-2875-11-240","volume":"11","author":"T Eshetu","year":"2012","unstructured":"Eshetu T, Abdo N, Bedru KH, Fekadu S, Wieser A, Pritsch M, et al. Open-label trial with artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria three years after its broad introduction in Jimma Zone. Ethiopia Malar J. 2012;11:240.","journal-title":"Ethiopia Malar J"},{"key":"5337_CR28","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1051\/parasite\/2009162129","volume":"16","author":"T Kefyalew","year":"2009","unstructured":"Kefyalew T, Animut A, Tamene T, Jima D, Hailemariam A, Legesse M. Efficacy of six-dose regimen of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria, three years after its introduction into Ethiopia. Parasite. 2009;16:129\u201334.","journal-title":"Parasite"},{"key":"5337_CR29","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/1475-2875-10-209","volume":"10","author":"J Hwang","year":"2011","unstructured":"Hwang J, Alemayehu BH, Hoos D, Melaku Z, Tekleyohannes SG, Teshi T, et al. In vivo efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria in Central Ethiopia. Malar J. 2011;10:209.","journal-title":"Malar J"},{"key":"5337_CR30","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/s12936-019-2864-1","volume":"18","author":"M Warsame","year":"2019","unstructured":"Warsame M, Hassan AM, Hassan AH, Jibril AM, Khim N, Arale AM, et al. High therapeutic efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Somalia. Malar J. 2019;18:231.","journal-title":"Malar J"},{"key":"5337_CR31","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1186\/s12936-018-2524-x","volume":"17","author":"MA Kakolwa","year":"2018","unstructured":"Kakolwa MA, Mahende MK, Ishengoma DS, Mandara CI, Ngasala B, Kamugisha E, et al. Efficacy and safety of artemisinin-based combination therapy, and molecular markers for artemisinin and piperaquine resistance in Mainland Tanzania. Malar J. 2018;17:369.","journal-title":"Malar J"},{"issue":"Suppl 1","key":"5337_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-8-S1-S4","volume":"8","author":"A Djimd\u00e9","year":"2009","unstructured":"Djimd\u00e9 A, Lef\u00e8vre G. Understanding the pharmacokinetics of Coartem\u00ae. Malar J. 2009;8(Suppl 1): s4.","journal-title":"Malar J"},{"key":"5337_CR33","unstructured":"WHO. Report on antimalarial drug efficacy, resistance and response. 10 years of surveillance. 2019. Geneva, World Health Organization. Available on-line: https:\/\/iris.who.int\/bitstream\/handle\/10665\/336692\/9789240012813-eng.pdf (Accessed on 30 Nov 2024)"},{"key":"5337_CR34","volume":"2012","author":"G Kinfu","year":"2012","unstructured":"Kinfu G, Gebre-selassie S, Fikrie N. Therapeutic efficacy of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Northern Ethiopia. Malar Res Treatment. 2012;2012: 548710.","journal-title":"Malar Res Treatment"},{"key":"5337_CR35","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1314981","volume":"371","author":"EA Ashley","year":"2014","unstructured":"Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2014;371:411\u201323.","journal-title":"N Engl J Med"},{"key":"5337_CR36","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1056\/NEJMoa2101746","volume":"385","author":"B Balikagala","year":"2021","unstructured":"Balikagala B, Fukuda N, Ikeda M, Katuro OT, Tachibana S-I, Yamauchi M, et al. Evidence of artemisinin-resistant malaria in Africa. N Engl J Med. 2021;385:1163\u201371.","journal-title":"N Engl J Med"},{"key":"5337_CR37","doi-asserted-by":"publisher","first-page":"718","DOI":"10.3201\/eid2404.170141","volume":"24","author":"M Ikeda","year":"2018","unstructured":"Ikeda M, Kaneko M, Tachibana SI, Balikagala B, Sakurai-Yatsushiro M, Yatsushiro S, et al. Artemisinin-resistant Plasmodium falciparum with high survival rates, Uganda, 2014\u20132016. Emerg Infect Dis. 2018;24:718\u201326.","journal-title":"Emerg Infect Dis"},{"key":"5337_CR38","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1093\/infdis\/jiab352","volume":"225","author":"J Straimer","year":"2022","unstructured":"Straimer J, Gandhi P, Renner KC, Schmitt EK. High prevalence of Plasmodium falciparum k13 mutations in Rwanda is associated with slow parasite clearance after treatment with artemether-lumefantrine. J Infect Dis. 2022;225:1411\u20134.","journal-title":"J Infect Dis"},{"key":"5337_CR39","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1038\/s41564-023-01461-4","volume":"8","author":"AA Fola","year":"2023","unstructured":"Fola AA, Feleke SM, Mohammed H, Brhane BG, Hennelly CM, Assefa A, et al. Plasmodium falciparum resistant to artemisinin and diagnostics have emerged in Ethiopia. Nat Microbiol. 2023;8:1911\u20139.","journal-title":"Nat Microbiol"},{"key":"5337_CR40","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1056\/NEJMc0805011","volume":"359","author":"H Noedl","year":"2008","unstructured":"Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukida MM, et al. Evidence of artemisinin-resistant malaria in Western Cambodia. N Engl J Med. 2008;359:2619\u201320.","journal-title":"N Engl J Med"},{"key":"5337_CR41","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/S1473-3099(13)70268-8","volume":"14","author":"AC Eziefula","year":"2014","unstructured":"Eziefula AC, Bousema T, Yeung S, Kamya M, Owaraganise A, Gabagaya G, et al. Single dose primaquine for clearance of Plasmodium falciparum gametocytes in children with uncomplicated malaria in Uganda\u202f: a randomised, controlled, double-blind, dose-ranging trial. Lancet Infect Dis. 2014;14:130\u20139.","journal-title":"Lancet Infect Dis"},{"key":"5337_CR42","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12916-016-0581-y","volume":"14","author":"BP Gon\u00e7alves","year":"2016","unstructured":"Gon\u00e7alves BP, Tiono AB, Ou\u00e9draogo A, Guelb\u00e9ogo WM, Bradley J, Nebie I, et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether lumefantrine in children with asymptomatic infection: a randomised, double-blind, placebo-controlled trial. BMC Med. 2016;14:40.","journal-title":"BMC Med"},{"key":"5337_CR43","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268820003167","volume":"149","author":"G Kishoyian","year":"2021","unstructured":"Kishoyian G, Njagi ENM, Orinda GO, Kimani FT, Thiongo K, Matoke-muhia D. Efficacy of artemisinin-lumefantrine for treatment of uncomplicated malaria after more than a decade of its use in Kenya. Epidemiol Infect. 2021;149: e27.","journal-title":"Epidemiol Infect"},{"key":"5337_CR44","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1056\/NEJMoa0808859","volume":"361","author":"AM Dondorp","year":"2009","unstructured":"Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009;361:455\u201367.","journal-title":"N Engl J Med"},{"key":"5337_CR45","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.4269\/ajtmh.20-0852","volume":"103","author":"MM Ippolito","year":"2020","unstructured":"Ippolito MM, Pringle JC, Siame M, Katowa B, Aydemir O, Oluoch PO, et al. Therapeutic efficacy of artemether-lumefantrine for uncomplicated falciparum malaria in Northern Zambia. Am J Trop Med Hyg. 2020;103:2224\u201332.","journal-title":"Am J Trop Med Hyg"},{"key":"5337_CR46","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12936-016-1091-2","volume":"15","author":"AO Hounto","year":"2016","unstructured":"Hounto AO, Azandossessi C, Lawani S, Damien G, Sissinto Y, de Tove YSS, et al. Therapeutic efficacy of artemether \u2013 lumefantrine for the treatment of uncomplicated falciparum malaria in northwest Benin. Malar J. 2016;15:37.","journal-title":"Malar J"},{"key":"5337_CR47","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.blre.2010.06.004","volume":"24","author":"G Garratty","year":"2010","unstructured":"Garratty G. Immune hemolytic anemia associated with drug therapy. Blood Rev. 2010;24:143\u201350.","journal-title":"Blood Rev"},{"key":"5337_CR48","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1186\/s12936-015-0881-2","volume":"14","author":"AM Gray","year":"2015","unstructured":"Gray AM, Arguin PM, Hamed K. Surveillance for the safety and effectiveness of artemether-lumefantrine in patients with uncomplicated Plasmodium falciparum malaria in the USA\u202f: a descriptive analysis. Malar J. 2015;14:349.","journal-title":"Malar J"},{"key":"5337_CR49","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1186\/s12936-015-0744-x","volume":"14","author":"YA Ebstie","year":"2015","unstructured":"Ebstie YA, Zeynudin A, Belachew T, Desalegn Z, Suleman S. Assessment of therapeutic efficacy and safety of artemether-lumefantrine ( Coartem \u00ae ) in the treatment of uncomplicated Plasmodium falciparum malaria patients in Bahir Dar district, Northwest Ethiopia\u202f: an observational cohort study. Malar J. 2015;14:236.","journal-title":"Malar J"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-025-05337-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-025-05337-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-025-05337-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T16:36:07Z","timestamp":1742315767000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-025-05337-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,18]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5337"],"URL":"https:\/\/doi.org\/10.1186\/s12936-025-05337-2","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,18]]},"assertion":[{"value":"7 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was obtained from the Scientific and Ethics Review Committee of the Centre for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), College of Health Sciences, Addis Ababa University (Protocol number:1851\/23) and the Ethiopian Public Health Institute (EPHI) (Protocol number:294\/2022) IRB office prior to the study\u2019s initiation. Permission was obtained from Shecha Health Centre. Written informed consent was obtained from each adult patient and from parent or guardian for children. Additionally, assent was obtained from children aged 12\u201317\u00a0years. Study details, including potential benefits and potential risks, were thoroughly explained to study participants before enrollment. Confidentiality was maintained, and participants were informed of their right to withdraw from the study at any time.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"89"}}